Is Exelixis Stock (EXEL) Halal? A Complete Analysis

The Short Answer

Exelixis stock (EXEL) is generally considered halal by most Islamic scholars and Sharia screening criteria. Exelixis is a commercial-stage oncology-focused biopharmaceutical company anchored by the cabozantinib franchise (Cabometyx), with a substantial net-cash balance sheet.

Oncology-pharmaceutical research, development, and commercialization is unambiguously permissible at the activity level under standard Sharia methodology — pharmaceutical activities aimed at preserving life (hifz al-nafs) are explicitly aligned with the higher objectives of Sharia (maqasid).

Sharia Screening Methodology

Islamic scholars use several criteria to screen stocks:

• Business activity screen: Is the company's primary business halal?
• Debt ratio: Total debt / market cap must be under 33%
• Interest income: Interest income / total revenue must be under 5%
• Haram revenue: Revenue from haram sources must be under 5%
• Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)

Exelixis' Business Activity

Exelixis is anchored by the cabozantinib franchise — sold under the Cabometyx brand for:

• Advanced renal cell carcinoma (kidney cancer) — one of the leading global treatments in the second-line and combination-therapy market
• Hepatocellular carcinoma (liver cancer)
• Differentiated thyroid cancer
• Combination therapy with immune-checkpoint inhibitors — including Bristol-Myers Squibb's Opdivo, materially expanding the addressable population

Exelixis also commercializes Cotellic (cobimetinib) in melanoma combination therapy under a partnership with Genentech/Roche, and develops a pipeline of next-generation oncology assets including:

• Zanzalintinib (XL092): A next-generation tyrosine-kinase inhibitor in late-stage colorectal-cancer, renal-cell-carcinoma, and other oncology trials
• XB002: A tissue-factor antibody-drug conjugate
• Broader portfolio: Small-molecule and antibody-drug-conjugate oncology assets

International commercialization of cabozantinib is partnered with Ipsen (ex-US ex-Japan) and Takeda (Japan).

Concerns to Be Aware Of

1. Net-Cash Position and Interest Income

Exelixis carries a substantial net-cash position. Interest income may be a non-trivial component of other-income relative to a smaller-cap biotech — verify against the 5% revenue threshold at the time of investment and apply purification of a small portion of any dividends or distributions, though Exelixis does not currently pay a regular dividend.

2. Franchise Concentration Risk

The majority of current revenue is derived from the Cabometyx franchise. Pipeline-asset development success will determine the durability of the franchise as the cabozantinib composition-of-matter patent estate eventually erodes.

3. Clinical-Trial Outcome Variance

Late-stage oncology trial readouts (including zanzalintinib in colorectal cancer and other indications) introduce binary-outcome risk. This is a business-investment consideration rather than a Sharia screen concern.

4. Research Materials

Some pharmaceutical research activities may involve animal-derived materials or biological samples in research processes. These are general-purpose biomedical-research considerations rather than direct-product concerns.

Financial Ratios (2025)

Based on Exelixis' most recent financial statements:

• Total Debt / Market Cap: Well below 33% threshold — net-cash balance sheet ✅
• Interest Income / Revenue: Verify against 5% threshold given net-cash position ⚠️
• Haram Revenue: Negligible ✅
• Business Activity: Permissible oncology pharmaceuticals ✅

Verdict from Major Screening Agencies

Exelixis stock is generally screened as compliant (halal) with purification by:

• Zoya App — Compliant with purification ✅
• MSCI Islamic criteria — Generally included ✅
• Most major Sharia advisory boards — Compliant with purification of small interest-income component ✅

Bottom Line

Exelixis (EXEL) is generally halal with purification for Muslim investors. The core business — oncology-pharmaceutical research, development, and commercialization — is unambiguously permissible at the activity level, and the financial screen passes comfortably with a net-cash balance sheet.

For Muslim investors seeking biotech and oncology-pharmaceutical exposure, EXEL sits alongside other halal-screened pharma names like Bristol-Myers Squibb (BMY), Eli Lilly (LLY), and Merck (MRK).